Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28831979 | 0.90 | PHF8 (0.33) | PHF8KDM2AMEN1KMT2ATSHR | |
| SCHEMBL15684245 | 0.90 | PHF8 (0.54) | PHF8KDM2ATSHRALDH1A1RAB9A | |
| SCHEMBL6222620 | 0.90 | ALDH1A1 (0.48) | PHF8KDM2AMEN1KMT2ATSHR | |
| SCHEMBL24703880 | 0.89 | ALDH1A1 (0.42) | PHF8KDM2AMEN1KMT2ATSHR | |
| SCHEMBL22205611 | 0.89 | LMNA (0.44) | PHF8KDM2AMEN1KMT2ATSHR | |
| SCHEMBL16050328 | 0.88 | TSHR (0.59) | PHF8KDM2AMEN1KMT2ATSHR | |
| SCHEMBL24096185 | 0.88 | PHF8 (0.32) | PHF8KDM2AMEN1KMT2A | |
| SCHEMBL99297 | 0.87 | — | — | |
| SCHEMBL29991123 | 0.87 | ALDH1A1 (0.41) | PHF8KDM2AALDH1A1LMNAHDAC6 | |
| SCHEMBL933822 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374376-A1 | ELECTROCHROMIC POLYMER HAVING PYRROLE DERIVATIVE AND THIOPHENE | AMBILIGHT INC (KY) | 2023-11-23 | — | — | US | claimed |
| US-20230374376-A1 | ELECTROCHROMIC POLYMER HAVING PYRROLE DERIVATIVE AND THIOPHENE | AMBILIGHT INC (KY) | 2023-11-23 | — | — | US | disclosed |
| US-20230374376-A1 | ELECTROCHROMIC POLYMER HAVING PYRROLE DERIVATIVE AND THIOPHENE | AMBILIGHT INC (KY) | 2023-11-23 | — | — | US | disclosed |
| US-20230374376-A1 | ELECTROCHROMIC POLYMER HAVING PYRROLE DERIVATIVE AND THIOPHENE | AMBILIGHT INC (KY) | 2023-11-23 | — | — | US | disclosed |
| WO-2023063954-A1 | ELECTROCHROMIC POLYMER HAVING PYRROLE DERIVATIVE AND THIOPHENE | AMBILIGHT INC. (KY) | 2023-04-20 | — | — | WO | disclosed |
| US-7576122-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7528163-B2 | N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye | MERCK & CO. INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080287489-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
| EP-1581503-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060276504-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-12-07 | — | — | US | disclosed |
| US-20060020000-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-01-26 | — | — | US | disclosed |
| EP-1581503-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004043354-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276504-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNJ11, KCNN1 | PHF8 1340/4885KDM2A 1712/4885MEN1 917/4885 |
| US-20080287489-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNJ11 | PHF8 988/4885KDM2A 1492/4885MEN1 754/4885 |
| US-20060020000-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNJ11 | PHF8 988/4885KDM2A 1492/4885MEN1 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.